Paris, August 29, 2010 (ots/PRNewswire) – Sanofi aventis announced today that the European Society of Cardiology (ESC) 2010 new Guidelines for the Management of Atrial Fibrillation (AF) have been released and recommend that Multaq(R) (dronedarone) should be used for maintenance of sinus rhythm as a first-line treatment option in all patients with paroxysmal and persistent [...]
Tag Archive > Nyha Class
Sanofi-aventis: Multaq(R) Receives Positive Recommendation by NICE in New Appraisal Consultation Document
Paris, March 30, 2010 (ots/PRNewswire) – Sanofi-aventis announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD)[1] for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for the management of patients with atrial fibrillation (AF). The NICE appraisal committee’s [...]
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Paris, November 30 (ots/PRNewswire) – – First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone – 400mg Tablets) in all 27 European member states. This approval follows the European [...]
Ferinject®: FAIR-HF study meets primary endpoints in patients with Iron Deficiency and Chronic Heart Failure
(pressebox) Bern, 02.10.2009, Vifor Pharma has reached an important milestone in its clinical development program: The FAIR-HF Study – a study assessing Ferinject® (ferric carboxymaltose) in patients with iron deficiency (with and without anaemia) and chronic heart failure – was recently completed and has met the primary endpoints. The detailed results will be presented at [...]
